Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Industry, Sector and Symbol:

Sector: Medical
Industry: Pharmaceuticals
Sub-Industry: N/A
Symbol: NASDAQ:TTPH
CUSIP: N/A
Web: www.tphase.com

Capitalization:

Market Cap: $334.4 million
Outstanding Shares: 51,053,000

Average Prices:

50 Day Moving Avg: $6.31
200 Day Moving Avg: $7.31
52 Week Range: $3.11 - $9.93

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -3.54
P/E Growth: -0.02

Sales & Book Value:

Annual Revenue: $5.01 million
Price / Sales: 66.75
Book Value: $2.67 per share
Price / Book: 2.45

Profitability:

EBIDTA: ($104,990,000.00)
Net Margins: -2,092.20%
Return on Equity: -79.79%
Return on Assets: -71.63%

Debt:

Current Ratio: 6.12%
Quick Ratio: 6.12%

Misc:

Average Volume: 1.26 million shs.
Beta: 2.59
Short Ratio: 0.89

Frequently Asked Questions for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.83) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.76) by $0.07. The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. Tetraphase Pharmaceuticals's revenue for the quarter was up 28.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.47) EPS. View Tetraphase Pharmaceuticals' Earnings History.

When will Tetraphase Pharmaceuticals make its next earnings announcement?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Tetraphase Pharmaceuticals.

Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?

6 brokers have issued twelve-month price objectives for Tetraphase Pharmaceuticals' stock. Their forecasts range from $4.00 to $15.00. On average, they anticipate Tetraphase Pharmaceuticals' share price to reach $11.80 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.

Are investors shorting Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 3,889,264 shares, an increase of 32.8% from the August 15th total of 2,927,894 shares. Based on an average daily volume of 856,396 shares, the days-to-cover ratio is presently 4.5 days. Approximately 7.7% of the shares of the company are sold short.

Who are some of Tetraphase Pharmaceuticals' key competitors?

Some companies that are related to Tetraphase Pharmaceuticals include Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Corium International (CORI), Teligent (TLGT), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP), Collegium Pharmaceutical (COLL), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Marinus Pharmaceuticals (MRNS), Aralez Pharmaceuticals (ARLZ), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Concordia International Corp. (CXRX) and SCYNEXIS (SCYX).

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the folowing people:

Leonard Patrick Gage Ph.D., Chairman of the Board of Directors
Guy Macdonald, President and Chief Executive Officer, Director
Christopher Watt, Principal Financial Officer, Principal Accounting Officer, Senior Vice President - Finance
Maria D. Stahl, Senior Vice President, General Counsel
Patrick T. Horn M.D. Ph.D., Chief Medical Officer
Jeffrey A. Chodakewitz M.D., Director
Geraldine A. Henwood Ph.D., Director
Garen G. Bohlin, Independent Director
John G. Freund M.D., Independent Director
Nancy J. Wysenski, Independent Director

Who owns Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Canada Pension Plan Investment Board (4.36%), Vanguard Group Inc. (2.78%), FMR LLC (2.62%), Dimensional Fund Advisors LP (2.16%), Tekla Capital Management LLC (1.97%) and Northern Trust Corp (1.74%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.

Who sold Tetraphase Pharmaceuticals stock? Who is selling Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Vanguard Group Inc., TIAA CREF Investment Management LLC, Russell Investments Group Ltd., FMR LLC, Wells Fargo & Company MN, Nationwide Fund Advisors and Teachers Advisors LLC. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

Who bought Tetraphase Pharmaceuticals stock? Who is buying Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Numeric Investors LLC, EcoR1 Capital LLC, Dimensional Fund Advisors LP, Strs Ohio, State Street Corp, Federated Investors Inc. PA, Northern Trust Corp and Quantitative Investment Management LLC. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

How do I buy Tetraphase Pharmaceuticals stock?

Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $6.55.

MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		207 (Vote Outperform)
Underperform Votes:		160 (Vote Underperform)
Total Votes:		367

MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	2 Hold Ratings, 4 Buy Ratings
Consensus Rating:	Buy (Score: 2.67)
Consensus Price Target:	$11.80 (80.15% upside)

Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/17/2017	Needham & Company LLC	Reiterated Rating	Hold		High
9/12/2017	Stifel Nicolaus	Reiterated Rating	Buy	$13.00	Low
8/28/2017	Piper Jaffray Companies	Initiated Coverage	Overweight -> Overweight	$14.00	High
7/26/2017	BMO Capital Markets	Reiterated Rating	Outperform	$12.00 -> $13.00	High
7/11/2017	HC Wainwright	Initiated Coverage	Buy -> Buy	$15.00	High
11/4/2016	Wedbush	Reiterated Rating	Neutral	$4.00	N/A
5/16/2016	Gabelli	Reiterated Rating	Neutral		N/A
11/19/2015	SunTrust Banks, Inc.	Upgrade	Neutral -> Buy	$12.00 -> $21.00	N/A

(Data available from 9/23/2015 forward)

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Earnings by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Earnings History by Quarter for Tetraphase Pharmaceuticals (NASDAQ TTPH)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/1/2017		($0.63)					N/A
8/2/2017	Q2 2017	($0.76)	($0.83)	$1.54 million	$1.59 million	View	N/A
5/2/2017	Q1 2017	($0.60)	($0.79)	$1.46 million	$1.48 million	View	N/A
3/8/2017	Q4	($0.60)	($0.61)	$1.28 million	$1.09 million	View	Listen
11/3/2016		($0.50)	($0.58)	$1.58 million	$0.90 million	View	N/A
8/4/2016	Q2	($0.46)	($0.47)	$2.05 million	$1.20 million	View	N/A
5/4/2016	Q1	($0.44)	($0.46)	$2.20 million	$2.00 million	View	N/A
2/23/2016	Q4	($0.44)	($0.50)	$3.23 million	$2.47 million	View	Listen
11/2/2015	Q315	($0.65)	($0.49)	$3.20 million	$2.90 million	View	N/A
8/5/2015	Q215	($0.62)	($0.72)	$2.73 million	$3.30 million	View	N/A
5/6/2015	Q115	($0.64)	($0.66)	$2.90 million	$3.00 million	View	N/A
3/5/2015		($0.54)	($0.69)	$2.74 million	$3.07 million	View	N/A
11/10/2014	Q314	($0.56)	($0.55)	$2.86 million	$2.29 million	View	N/A
8/12/2014	Q214	($0.54)	($0.71)	$2.79 million	$1.30 million	View	N/A
5/12/2014	Q114	($0.45)	($0.53)	$2.97 million	$2.50 million	View	N/A
3/6/2014		($0.46)	($0.49)			View	N/A
11/11/2013	Q3	($0.39)	($0.49)	$2.43 million	$2.20 million	View	N/A
5/13/2013	Q113	($0.27)	($0.30)	$2.49 million	$2.70 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

2017 EPS Consensus Estimate: ($2.29)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	2	($0.62)	($0.56)	($0.59)
Q2 2017	2	($0.63)	($0.58)	($0.61)
Q3 2017	2	($0.61)	($0.59)	($0.60)
Q4 2017	2	($0.53)	($0.46)	($0.50)

(Data provided by Zacks Investment Research)

Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 41.73%

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/22/2017	Jacques Dumas	Insider	Sell	17,500	$6.00	$105,000.00
8/17/2017	Jacques Dumas	Insider	Sell	7,155	$5.86	$41,928.30
3/15/2017	L Patrick Gage	Director	Buy	11,000	$7.49	$82,390.00
9/1/2015	Guy Macdonald	insider	Sell	10,000	$41.57	$415,700.00
8/14/2015	David Charles Lubner	CFO	Sell	9,500	$42.92	$407,740.00
8/13/2015	Patrick Taylor Horn	Insider	Sell	10,000	$44.69	$446,900.00
8/12/2015	L Patrick Gage	Director	Sell	15,000	$45.00	$675,000.00
7/20/2015	Guy Macdonald	Insider	Sell	15,000	$50.72	$760,800.00
7/14/2015	David Charles Lubner	CFO	Sell	7,500	$48.92	$366,900.00
7/13/2015	Patrick Taylor Horn	Insider	Sell	10,000	$48.93	$489,300.00
7/6/2015	John Craig Thompson	COO	Sell	10,000	$47.91	$479,100.00
7/1/2015	Guy Macdonald	Insider	Sell	10,000	$47.92	$479,200.00
6/15/2015	David Charles Lubner	CFO	Sell	17,500	$41.45	$725,375.00
6/15/2015	John Craig Thompson	COO	Sell	10,000	$41.51	$415,100.00
6/8/2015	John Craig Thompson	COO	Sell	22,499	$43.26	$973,306.74
6/1/2015	Guy Macdonald	Insider	Sell	16,087	$41.89	$673,884.43
5/11/2015	Guy Macdonald	Insider	Sell	20,000	$41.51	$830,200.00
1/20/2015	Guy Macdonald	Insider	Sell	34,135	$36.59	$1,248,999.65
10/2/2014	John Gordon Freund	Director	Sell	247,734	$20.88	$5,172,685.92
10/1/2014	John Gordon Freund	Director	Sell	142,146	$20.84	$2,962,322.64
9/30/2014	John Gordon Freund	Director	Sell	152,266	$20.18	$3,072,727.88
9/29/2014	John Gordon Freund	Director	Sell	95,648	$20.19	$1,931,133.12
9/23/2014	Guy Macdonald	Insider	Sell	10,000	$18.47	$184,700.00
9/17/2014	Guy Macdonald	Insider	Sell	10,000	$18.00	$180,000.00
9/17/2014	John Gordon Freund	Director	Sell	144,356	$17.21	$2,484,366.76
9/12/2014	John Gordon Freund	Director	Sell	55,644	$17.01	$946,504.44
9/8/2014	John Gordon Freund	Director	Sell	16,700	$15.01	$250,667.00
9/4/2014	John Gordon Freund	Director	Sell	183,300	$15.05	$2,758,665.00
9/3/2014	John Gordon Freund	Director	Sell	142,100	$15.04	$2,137,184.00
8/20/2014	Guy Macdonald	Insider	Sell	10,000	$11.59	$115,900.00
7/18/2014	Guy Macdonald	Insider	Sell	15,000	$10.61	$159,150.00
6/23/2014	John Gordon Freund	Director	Sell	47,184	$13.77	$649,723.68
6/20/2014	John Gordon Freund	Director	Sell	152,816	$13.39	$2,046,206.24
6/17/2014	David Charles Lubner	CFO	Sell	13,530	$12.51	$169,260.30
6/17/2014	Guy Macdonald	Insider	Sell	15,000	$12.28	$184,200.00
5/19/2014	Guy Macdonald	Insider	Sell	15,000	$9.00	$135,000.00
5/19/2014	Steven Ph.D. Gullans	Director	Buy	25,000	$9.24	$231,000.00
5/14/2014	L Patrick Gage	Director	Buy	5,000	$9.25	$46,250.00
4/14/2014	Guy Macdonald	Insider	Sell	15,000	$9.69	$145,350.00
3/20/2014	Joyce Sutcliffe	SVP	Sell	11,494	$12.41	$142,640.54
3/6/2014	David Charles Lubner	CFO	Sell	4,510	$13.65	$61,561.50
2/20/2014	Joyce Sutcliffe	SVP	Sell	11,494	$14.00	$160,916.00
2/12/2014	David Charles Lubner	CFO	Sell	4,506	$13.92	$62,723.52
2/7/2014	David Charles Lubner	CFO	Sell	9,928	$14.22	$141,176.16
2/5/2014	Joyce Sutcliffe	SVP	Sell	11,494	$13.93	$160,111.42
9/18/2013	Ventures Vi Lp Cmea	major shareholder	Sell	100,000	$10.20	$1,020,000.00
9/17/2013	Ventures Vi Lp Cmea	major shareholder	Sell	53,468	$9.26	$495,113.68
3/25/2013	John Gordon Freund	Director	Buy	681,012	$7.00	$4,767,084.00
3/25/2013	Medical Fund Lp Excel	Major Shareholder	Buy	496,121	$7.00	$3,472,847.00
3/20/2013	Fmr Llc	Insider	Buy	642,857	$7.00	$4,499,999.00

(Data available from 1/1/2013 forward)

Headline Trends for Tetraphase Pharmaceuticals (NASDAQ:TTPH) Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Source:

Date	Headline
	Tetraphase Pharmaceuticals, Inc. (TTPH) Downgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - September 22 at 7:40 PM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by Needham & Company LLC www.americanbankingnews.com - September 17 at 8:58 AM
	Tetraphase Pharmaceuticals: Funding Completed, On To The Next Catalyst - Seeking Alpha seekingalpha.com - September 17 at 8:51 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Short Interest Update www.americanbankingnews.com - September 16 at 1:20 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - September 15 at 2:32 AM
	Tetraphase Pharmaceuticals' (TTPH) "Buy" Rating Reiterated at Stifel Nicolaus www.americanbankingnews.com - September 12 at 11:23 AM
	$1.46 Million in Sales Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter www.americanbankingnews.com - September 12 at 1:36 AM
	Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections finance.yahoo.com - September 11 at 7:59 AM
	Tetraphase Pharmaceuticals Inc (TTPH) Expected to Announce Earnings of -$0.56 Per Share www.americanbankingnews.com - September 11 at 12:08 AM
	Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences finance.yahoo.com - September 5 at 9:32 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - September 2 at 11:16 AM
	ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : September 1, 2017 finance.yahoo.com - September 1 at 10:08 AM
	Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : August 31, 2017 finance.yahoo.com - August 31 at 11:20 AM
	Zacks Investment Research Lowers Tetraphase Pharmaceuticals, Inc. (TTPH) to Hold www.americanbankingnews.com - August 30 at 11:36 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Coverage Initiated at Piper Jaffray Companies www.americanbankingnews.com - August 28 at 11:20 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Sees Large Increase in Short Interest www.americanbankingnews.com - August 28 at 1:48 AM
	Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 finance.yahoo.com - August 25 at 11:54 AM
	Analysts Expect Tetraphase Pharmaceuticals, Inc. (TTPH) Will Post Quarterly Sales of $1.46 Million www.americanbankingnews.com - August 25 at 6:00 AM
	Insider Selling: Tetraphase Pharmaceuticals, Inc. (TTPH) Insider Sells 17,500 Shares of Stock www.americanbankingnews.com - August 24 at 7:58 PM
	-$0.58 EPS Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter www.americanbankingnews.com - August 23 at 12:20 PM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Upgraded by BidaskClub to "Hold" www.americanbankingnews.com - August 22 at 12:44 PM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Insider Sells $41,928.30 in Stock www.americanbankingnews.com - August 21 at 8:10 PM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - August 21 at 2:26 AM
	Contrasting Tetraphase Pharmaceuticals (TTPH) and Pernix Therapeutics Holdings (PTX) www.americanbankingnews.com - August 20 at 4:22 PM
	Tetraphase Pharma (TTPH) Announces Submission and Validation of IV Eravacycline Marketing Authorization ... - StreetInsider.com www.streetinsider.com - August 18 at 8:11 AM
	Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency finance.yahoo.com - August 17 at 8:39 AM
	Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock www.zacks.com - August 16 at 8:28 AM
	Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Upgraded at Zacks Investment Research www.americanbankingnews.com - August 9 at 9:10 AM
	Analysts Anticipate Tetraphase Pharmaceuticals, Inc. (TTPH) Will Post Quarterly Sales of $1.46 Million www.americanbankingnews.com - August 7 at 9:12 AM
	Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.'s Q3 2017 Earnings (NASDAQ:TTPH) www.americanbankingnews.com - August 7 at 7:12 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Earnings of -$0.65 Per Share www.americanbankingnews.com - August 5 at 7:08 AM
	Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : August 4, 2017 finance.yahoo.com - August 4 at 9:20 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS www.americanbankingnews.com - August 3 at 9:20 PM
	Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Achievements finance.yahoo.com - August 3 at 8:13 AM
	Tetraphase reports 2Q loss finance.yahoo.com - August 3 at 8:13 AM
	Tetraphase Pharma Decides to Reap Profits With Secondary Offering finance.yahoo.com - July 29 at 8:05 AM
	FY2017 Earnings Estimate for Tetraphase Pharmaceuticals, Inc. Issued By Gabelli (TTPH) www.americanbankingnews.com - July 28 at 11:47 AM
	Pre-Market Most Active for Jul 28, 2017 : TTPH, BTI, QQQ, SBUX, USLV, TVIX, TEF, WFM, XOM, X, STM, TWTR - Nasdaq www.nasdaq.com - July 28 at 9:12 AM
	Tetraphase Pharmaceuticals: IGNITE4 Data Igniting Share Price - Seeking Alpha seekingalpha.com - July 28 at 9:12 AM
	Tetraphase Pharma (TTPH) Prices 10M Shares at $6.50/Sh - StreetInsider.com www.streetinsider.com - July 28 at 9:12 AM
	Tetraphase Announces Pricing of Public Offering of Common Stock finance.yahoo.com - July 28 at 9:11 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - July 27 at 6:42 PM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Earns "Hold" Rating from Needham & Company LLC www.americanbankingnews.com - July 27 at 5:14 PM
	Stifel Upgrades Tetraphase Pharmaceuticals (TTPH) to Buy, $15 PT - StreetInsider.com www.streetinsider.com - July 27 at 8:42 AM
	Tetraphase Pharma (TTPH) Reports $60M Offering of Common Stock - StreetInsider.com www.streetinsider.com - July 27 at 8:41 AM
	Here's Why Tetraphase Pharmaceuticals Rose as Much as 26.8% Today finance.yahoo.com - July 27 at 8:41 AM
	Tetraphase Pharmaceuticals Inc (TTPH) Investors Are Parading Today, But Needham Cautious on the Long-Term finance.yahoo.com - July 27 at 8:41 AM
	Tetraphase Announces Proposed Public Offering of Common Stock finance.yahoo.com - July 27 at 8:41 AM
	Today's Research Reports on Stocks to Watch: Argos Therapeutics and Tetraphase Pharmaceuticals finance.yahoo.com - July 27 at 8:41 AM
	Tetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by BMO Capital Markets www.americanbankingnews.com - July 26 at 12:29 PM